Post-licensure passive safety surveillance of rotavirus vaccines: Reporting sensitivity for intussusception

被引:6
|
作者
Perez-Vilar, S. [1 ]
Diez-Domingo, J. [1 ]
Gomar-Fayos, J. [2 ]
Pastor-Villalba, E. [3 ]
Sastre-Canton, M. [1 ]
Puig-Barbera, J. [1 ]
机构
[1] FISABIO Salud Publ, Area Invest Vacunas, Fdn Fomento Invest Sanitaria & Biomed Comunidad V, Valencia, Spain
[2] Direcc Gen Farm & Prod Sanitarios, Serv Ordenac & Control Medicamento, Valencia, Spain
[3] Direcc Gen Salud Publ, Serv Salud Infantil & Mujer, Valencia, Spain
来源
ANALES DE PEDIATRIA | 2014年 / 81卷 / 02期
关键词
Rotavirus vaccines; Pharmacovigilance; Intussusception; ADVERSE EVENTS; VACCINATION; RISK; PENTAVALENT; HOSPITALIZATIONS; IMMUNIZATION; CHILDREN; INFANTS; DISEASE;
D O I
10.1016/j.anpedi.2013.10.027
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: The aims of this study were to describe the reports of suspected adverse events due to rotavirus vaccines, and assess the reporting sensitivity for intussusception. Material and methods: Descriptive study performed using the reports of suspected adverse events following rotavirus vaccination in infants aged less than 10 months, as registered in the Pharmacovigilance Centre of the Valencian Community during 2007-2011. The reporting rate for intussusception was compared to the intussusception rate in vaccinated infants obtained using the hospital discharge database (CMBD), and the regional vaccine registry. Results: The adverse event reporting rate was 20 per 100,000 administered doses, with the majority (74%) of the reports being classified as non-serious. Fever, vomiting, and diarrhea were the adverse events reported more frequently. Two intussusception cases, which occurred within the first seven days post-vaccination, were reported as temporarily associated to vaccination. The reporting sensitivity for intussusception at the Pharmacovigilance Centre in the 1-7 day interval following rotavirus vaccination was 50%. Conclusions: Our results suggest that rotavirus vaccines have, in general, a good safety profile. Intussusception reporting to the Pharmacovigilance Centre shows sensitivity similar to other passive surveillance systems. The intussusception risk should be further investigated using well-designed epidemiological studies, and evaluated in comparison with the well-known benefits provided by these vaccines. (C) 2013 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:77 / 85
页数:9
相关论文
共 50 条
  • [21] Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015
    Miller, Elaine R.
    Lewis, Paige
    Shimabukuro, Tom T.
    Su, John
    Moro, Pedro
    Woo, Emily Jane
    Jankosky, Christopher
    Cano, Maria
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1963 - 1969
  • [22] Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia
    Buttery, J. P.
    Danchin, M. H.
    Lee, K. J.
    Carlin, J. B.
    McIntyre, P. B.
    Elliott, E. J.
    Booy, R.
    Bines, J. E.
    VACCINE, 2011, 29 (16) : 3061 - 3066
  • [23] Statistical performance of group sequential methods for observational post-licensure medical product safety surveillance: A simulation study
    Zhao, Shanshan
    Cook, Andrea
    Jackson, Lisa
    Nelson, Jennifer
    STATISTICS AND ITS INTERFACE, 2012, 5 (04) : 381 - 390
  • [24] Safety and tolerability of bivalent HPV vaccine An italian post-licensure study
    Gasparini, Roberto
    Bonanni, Paolo
    Levi, Miriam
    Bechini, Angela
    Boccalini, Sara
    Tiscione, Emilia
    Amicizia, Daniela
    Lai, Piero Luigi
    Sulaj, Klodiana
    Patria, Antonio Giuseppe
    Panatto, Donatella
    HUMAN VACCINES, 2011, 7 : 136 - 146
  • [25] The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise
    Michael Nguyen
    Ball, Robert
    Midthun, Karen
    Lieu, Tracy A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 291 - 297
  • [26] Post-licensure rapid immunization safety monitoring program (PRISM) data characterization
    Baker, Meghan A.
    Michael Nguyen
    Cole, David V.
    Lee, Grace M.
    Lieu, Tracy A.
    VACCINE, 2013, 31 : K98 - K112
  • [27] Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine
    Baxter, Roger
    Hansen, John
    Timbol, Julius
    Pool, Vitali
    Greenberg, David P.
    Johnson, David R.
    Decker, Michael D.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (11) : 2742 - 2748
  • [28] Post-licensure safety surveillance for human papillomavirus-16/18AS04-adjuvanted vaccine: more than 4 years of experience
    Angelo, Maria-Genalin
    Zima, Julia
    Da Silva, Fernanda Tavares
    Baril, Laurence
    Arellano, Felix
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (05) : 456 - 465
  • [29] Post-licensure experience with rotavirus vaccination in Latin America and the Caribbean: a systematic review and meta-analysis
    Chavers, Tyler
    De Oliveira, Lucia H.
    Parashar, Umesh D.
    Tate, Jacqueline E.
    EXPERT REVIEW OF VACCINES, 2018, 17 (11) : 1037 - 1051
  • [30] Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children
    Hansen, J.
    Zhang, L.
    Eaton, A.
    Baxter, R.
    Robertson, C. A.
    Decker, M. D.
    Greenberg, D. P.
    Bassily, E.
    Klein, N. P.
    VACCINE, 2018, 36 (16) : 2133 - 2138